Libromide 325 mg Oral Tablets for Dogs

Main information

  • Trade name:
  • Libromide 325 mg Oral Tablets for Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Libromide 325 mg Oral Tablets for Dogs
    Hungary
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Bromides
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0400/001
  • Authorization date:
  • 28-09-2011
  • EU code:
  • UK/V/0400/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:June2013

AN:01432/2012

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Libromide325mgTabletsforDogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Potassiumbromide 325mg

ForfulllistofexcipientsseeSection6.1

3. PHARMACEUTICALFORM

Tablet.

Plainwhitecircularbiconvex9.5mmtabletwithasinglescoredlineononeface.

Thetabletscanbedividedintoequalhalves.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs

4.2 Indicationsforuse,specifyingthetargetspecies

Ananti-epilepticagentforuseasanadjuncttophenobarbitalinthecontrolof

refractorycasesofepilepsyindogs.

4.3 Contraindications

Donotuseincasesofknownhypersensitivitytobromide,ortoanyofthe

excipients.

Donotuseindogswithsevererenalinsufficiency.

4.4 Specialwarningsforeachtargetspecies

Itisadvisablenottochangethedog’sdietduringtherapyduetotheeffectof

chlorideintakeonserumbromideconcentrations,seesection4.8.

4.5 Specialprecautionsforuse

i Specialprecautionsforuseinanimals

Donotabruptlydiscontinuetherapyasthismayprecipitate

seizures.

Incasesofrenalinsufficiency,inordertopreventbromide

accumulation(seesection5.2),administerareduceddoseof

Libromideandmonitorthedogclosely.

Areductioninchlorideintakecouldcausebromideintoxication

(seesection4.8).

Revised:June2013

AN:01432/2012

Page2of6

Administrationonanemptystomachmayinducevomiting.

Dogsweighinglessthan11kgcannotbeaccuratelydosedwith

therecommendedinitialdoserateof15mg/kgtwicedailyas

theminimumdoseachievablebydivisionoftheLibromide

325mgtabletis162.5mg,seesection4.9.

Potentiallyseveresideeffectscanbeassociatedwiththeuse

ofpotassiumbromideincats.

iiSpecialprecautionsforthepersonadministeringtheveterinary

medicinalproducttoanimals

Donothandlethisproductifyouarepregnant,thinkyouare

pregnantorifyouarebreastfeeding.

Donotusethisproductifyouhaveaknownsensitivityto

bromide.

Washhandsthoroughlyimmediatelyafterbreakingorhandling

anytablets.

Discontinuehandlingthisproductifyoudevelopanysignsof

skinirritation,includingitchiness,rash,peelingorflakingofskin

orredness.Incaseofirritationoftheskinoreyes,orincaseof

accidentalself-administration,seekmedicaladviceimmediately

andshowthepackageleafletorthelabeltothephysician.

Tothephysician:

Bromideintoxicationcanbetreatedbyadministrationofsodium

chlorideorasuitablechlorureticagent.

4.6 Adversereactions(frequencyandseriousness)

Commonlyreportedadversereactionsincludepolyuria/polydipsia,polyphagia,

vomiting,somnolence,ataxia(hindendweaknessandlossofcoordination),nausea

anderythematousdermatitis(bromiderash).Inrarecasestransientdiarrhoeamay

occur.

Dogsreceivingpotassiumbromideincombinationwithphenobarbitalwillcommonly

exhibitelevatedserumpancreaticlipaseimmunoreactivityconcentrations(cPLI)

whichmayormaynotbeassociatedwithclinicalsignsofpancreatitis.

Incasesofpancreatitisordermatitis,symptomatictreatmentmayberequired.

Uncommonadversereactionsalsoincludebehaviouralchangessuchasirritability

orrestlessness.

Adverseclinicalsignswhichmayappearindogsonhigherdosesoftherapyusually

disappearfollowingareductionindose.Ifthedogistoosedated,assesstheserum

concentrationsofbothbromideandphenobarbitaltodeterminewhetherthedoseof

eithershouldbereduced.

Revised:June2013

AN:01432/2012

Page3of6

Ifthedoseisreduced,measuretheserumbromideconcentrationtoensureit

remainswithinthetherapeuticrange.

4.7 Useduringpregnancy,lactationorlay

Safetyhasnotbeenestablishedduringpregnancyorlactationindogs.Although

therewasnoevidenceofreproductivetoxicityinlaboratoryanimals,bromidecan

crosstheplacentaandcasesofneonatalbromidetoxicityhavebeenreportedin

humans.Intheabsenceofspecificdata,continueduseduringpregnancyshould

besubjecttoabenefit/riskassessmentbytheresponsibleveterinarian.

Sincebromidemaybeexcretedintomilk,monitornursingpuppiesfor

somnolescence/sedativeeffects;ifnecessary,considerearlyweaning,oran

artificialsucklingmethod.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Bromideandchloridecompeteforre-absorptionbythekidneys.Increasingdietary

chloride(salt)intakewilldecreaserenalre-absorptionofbromide,causing

decreasedserumbromideconcentrations,whichcouldleadtoseizures.

Conversely,changingtoadietlowinchloridewillincreaseserumbromide

concentrations,whichcouldcausebromideintoxication(seesection4.10).

Loopdiuretics(e.g.furosemide)canincreasebromideexcretion,loweringserum

bromideconcentrations.

Administrationoffluidsordrugformulationscontainingchloridecanlowerserum

bromideconcentrations.

BromideissynergisticwithotherGABA-ergicdrugssuchasphenobarbital.

4.9 Amount(s)tobeadministeredandadministrationroute

Fororaluse.Administerwithfood.

Administertodogswithrefractoryepilepsy,whereseizurecontrolisunsatisfactory

despiteappropriatephenobarbitaltherapy,whenserumphenobarbital

concentrationsareatasteady-statewithinthetherapeuticrange.

Thedoseshouldbetitratedtotheindividualdogastherequireddosagewilldepend

onthenatureandseverityoftheunderlyingdisease.

Administerwithfoodataninitialdoseof15mg/kgbodyweighttwicedaily

(equivalenttoatotaldailydoseof30mg/kg).Twicedailyadministrationisadvised

inordertoreducetheriskofgastrointestinaldisturbances.Duetothe24dayhalf-

lifeofbromide,itcantakeseveralweeksormonthstoachievesteady-stateserum

concentrations.

Foratleastthefirstthreemonthsfollowingcommencementoftherapy,measure

serumbromideconcentrationsevery4weeks.Theexpectedtherapeuticserum

bromideconcentration(whenusedinconjunctionwithphenobarbital)is800to2000

µg/ml.Adjustmentstothedoseshouldbemadewithregardtothefrequencyof

seizures,thehalf-lifeofbromideandtheserumbromideconcentration.

Revised:June2013

AN:01432/2012

Page4of6

Longtermmonitoringofserumbromide(andassociatedphenobarbital)

concentrationsshouldbeperformedasclinicallyjustifiedbytheindividualcase.

Closemonitoringforsideeffectsisadvisableathigherserumbromide

concentrations.

Useindogswithabodyweightoflessthan11kgshouldbesubjecttoarisk/benefit

assessment,seesection4.5.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Clinicalsignsofbromidetoxicity,suchasataxia,somnolence,nauseaand

pancreatitismayoccurindogswhenahighdoseisadministered.

Ifoverdoseissuspected,immediatelyreducethedosage.Closelymonitorthe

serumbromideconcentrationinordertoestablishanappropriatetherapeutic

concentration.

Incasesofoverdose,ifnecessaryandappropriate,administer0.9%sodium

chloridesolutionintravenouslytoreduceserumbromideconcentrations.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Psycholeptics:otherhypnoticsandsedatives:

bromides.

ATCVetCode:QN05CM11.

5.1 Pharmacodynamicproperties

Potassiumbromideisahalideanticonvulsant.Bromidereplaceschlorideinallbody

fluids.Itcompeteswithchloridetransportacrossnervecellmembranesandinhibits

sodiumtransportandsocausesmembranehyperpolarisation.This

hyperpolarisationraisestheseizurethresholdandpreventsthespreadofepileptic

discharges.Bromidehaseffectsonactivetransportacrossglialcellmembranes

andaffectspassivemovementsofionsbycompetitionwithchlorideforanion

channelsinpost-synapticmembranesthatareactivatedbyinhibitory

neurotransmitters.ThispotentiatestheeffectofGABAwhichresultsinasynergistic

activityofbromidewithotherdrugsthathaveGABA-ergicactivity.

5.2 Pharmacokineticproperties

Thepharmacokineticsofpotassiumbromidehasbeenstudiedindogs.Thehalf-life

isapproximately24days.Duetothisextremelylonghalflife,itcantakeseveral

weeks/monthstoachievesteadystateconcentrations.Potassiumbromideiswell

absorbedorallywithpeakabsorptioninabout1.5hours.Onceingested,the

potassiumbromidesaltdissociates,andthebromideionisrapidlyabsorbedbythe

gastrointestinaltract.

Afterabsorption,thebromideionrapidlydistributes,asdoeschloride,throughout

theextra-cellularspaceandintocells.Chlorideisdistributedpassivelyacrossmost

Revised:June2013

AN:01432/2012

Page5of6

cellmembranesaccordingtothetrans-membranepotential,anditislikelythat

bromidedistributesinthesamemanner.Asthebromideconcentrationisincreased

inthebody,theconcentrationofchlorideisdecreasedindirectproportiontothe

increaseinbromide.

Bromideisnotmetabolisedbythebody,itentersandleavesthebodyonlyasthe

monovalentanion.Excretionofbromideismainlyviathekidneys,whereit

competeswithchloridefortubularreabsorption.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Lactosemonohydrate

Microcrystallinecellulose

Magnesiumstearate

Stearicacid

Saccharinsodium

6.2 Incompatibilities

Notapplicable.

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelflifeafterfirstopeningtheimmediatepackaging:3months.

Useanyhalvedtabletwithin12hours.

6.4 Specialprecautionsforstorage

Donotstoreabove25°C.

Keepthetabletcontainertightlyclosedinordertoprotectfrommoisture.

6.5 Natureandcompositionofimmediatepackaging

Packsizes:100and500tablets.

White,polypropylenecontainerwithpolypropylene,childresistantclosure.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproduct

orwastematerialsderivedfromtheuseofsuchproducts,ifappropriate

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Revised:June2013

AN:01432/2012

Page6of6

7. MARKETINGAUTHORISATIONHOLDER

DechraLimited

DechraHouse

JamageIndustrialEstate

Stoke-on-Trent

Staffordshire

ST71XW

8. MARKETINGAUTHORISATIONNUMBER

Vm

10434/4073

9. DATEOFFIRSTAUTHORISATION

Date:4February2010

10. DATEOFREVISIONOFTHETEXT

Date:June2013

APPROVED 27/06/13

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

9-11-2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in ...

FDA - U.S. Food and Drug Administration

3-10-2018

Prijsonderhandelingen dure medicijnen leiden tot forse kostenverlaging

Prijsonderhandelingen dure medicijnen leiden tot forse kostenverlaging

Sinds enkele jaren onderhandelt de minister voor Medische Zorg met fabrikanten van nieuwe en zeer dure geneesmiddelen. Doel is om deze waardevolle innovatieve geneesmiddelen tegen aanvaardbare kosten toegankelijk te maken en te houden voor de patiënt. Dit heeft in 2017 geleid tot een kostenverlaging van in totaal 132 miljoen euro. Dat heeft minister Bruno Bruins aan de Tweede Kamer laten weten. Op basis van de prijs die fabrikanten eerst vroegen zou er sprake zijn van 457 miljoen aan uitgaven aan de betr...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

15-8-2018

G Female Oral Tablets

G Female Oral Tablets

G Female Oral Tablets pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

15-3-2018

Duro-K 600 mg potassium chloride tablets

Duro-K 600 mg potassium chloride tablets

Advisory – lead content may exceed regulatory guidelines

Therapeutic Goods Administration - Australia

24-5-2018

Ultibro Breezhaler (Novartis Europharm Limited)

Ultibro Breezhaler (Novartis Europharm Limited)

Ultibro Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Renewal - Commission Decision (2018)3259 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2679/R/24

Europe -DG Health and Food Safety